Crinetics Approach

News Releases

News Releases

April 15, 2020
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the
April 14, 2020
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , April 14, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it
January 8, 2020
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
SAN DIEGO , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that